ArticleBMC infectious diseases2017
GeneXpert HIV-1 quant assay, a new tool for scale up of viral load monitoring in the success of ART programme in India.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Point-of-care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities.The Cochrane database of systematic reviews · 2022Pooled it
- Performance of Cepheid Xpert HIV-1 viral load plasma assay to accurately detect treatment failure.AIDS (London, England) · 2019Pooled it
- Performance of the Xpert HIV-1 Viral Load Assay: a Systematic Review and Meta-analysis.Journal of clinical microbiology · 2018Pooled it
- Evaluating the accuracy of HIV-1 viral load testing using near point of care Xpert HIV-1 system at Solwezi general hospital, Zambia.BMC research notes · 2025Article
- Real-world performance of point-of-care vs. standard-of-care HIV viral load testing in western Kenya: Secondary analysis of Opt4Kids and Opt4Mamas studies.PLOS global public health · 2024Article
- Article
- Near point-of-care HIV viral load testing: Cascade after high viral load in suburban Yangon, Myanmar.PloS one · 2023Article
- Implementation of an interactive mobile application to pilot a rapid assay to detect HIV drug resistance mutations in Kenya.PLOS global public health · 2022Article
- Article
- Study To Evaluate the Performance of a Point-of-Care Whole-Blood HIV Viral Load Test (SAMBA II HIV-1 Semi-Q Whole Blood).Journal of clinical microbiology · 2021Article
- Anti-retroviral therapy failure in HIV-1 infected pregnant women and its associated risk of HIV transmission.Archives of gynecology and obstetrics · 2020Observational
- The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau.AIDS research and therapy · 2020Article
- Performance Comparison of Xpert HIV-1 Viral Load Assay and Roche Taqman and Abbott M2000 RT in Bamako, Mali.Journal of AIDS & clinical research · 2020Article
- Point-of-Care HIV Viral Load Testing: an Essential Tool for a Sustainable Global HIV/AIDS Response.Clinical microbiology reviews · 2019Review
- Performance and usability of Cepheid GeneXpert HIV-1 qualitative and quantitative assay in Kenya.PloS one · 2019Article
- Assessment of eight nucleic acid amplification technologies for potential use to detect infectious agents in low-resource settings.PloS one · 2019Article
- HIV prevention strategies and risk of infection: a model-based analysis.Epidemiology and infection · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundRecent WHO guidelines identify virologic monitoring for diagnosing and confirming ART failure. In view of this, validation and scale up of point of care viral load technologies is essential in resource limited settings.
methodsA systematic validation of the GeneXpert® HIV-1 Quant assay (a point-of-care technology) in view of scaling up HIV-1 viral load in India to monitor the success of national ART programme was carried out. Two hundred nineteen plasma specimens falling in nine viral load ranges (<40 to >5 L copies/ml) were tested by the Abbott m2000rt Real Time and GeneXpert HIV-1 Quant assays. Additionally, 20 seronegative; 16 stored specimens and 10 spiked controls were also tested. Statistical analysis was done using Stata/IC and sensitivity, specificity, PPV, NPV and %misclassification rates were calculated as per DHSs/AISs, WHO, NACO cut-offs for virological failure.
resultsThe GeneXpert assay compared well with the Abbott assay with a higher sensitivity (97%), specificity (97-100%) and concordance (91.32%). The correlation between two assays (r = 0.886) was statistically significant (p < 0.01), the linear regression showed a moderate fit (R
conclusionThe viral load results of GeneXpert HIV-1 Quant assay compared well with Abbott HIV-1 m2000 Real Time PCR; suggesting its use as a Point of care assay for viral load estimation in resource limited settings. Its ease of performance and rapidity will aid in timely diagnosis of ART failures, integrated HIV-TB management and will facilitate the UNAIDS 90-90-90 target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.